drugset

drugset / Trial / NCT01136226

Evaluate Recovery of Testosterone for Patients Using Eligard

NCT01136226 ↗

Phase 4 Completed 42 enrolled Chesapeake Urology Research Associates Sanofi-Synthelabo · collab

NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to determine if testosterone will recover to 90% by year 1 after using Eligard.

Timeline

Start: 2003-10
Primary completion: 2009-06
Completion: 2009-06

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Eligard (TM)	Unknown	22.5 mg	Subcutaneous

Indications